

(FINAL/APPROVED)

VIRGINIA BOARD OF PHARMACY
MINUTES OF A PANEL OF THE BOARD

Thursday, March 29, 2018
Commonwealth Conference Center
Second Floor
Board Room 4

Department of Health Professions
Perimeter Center
9960 Mayland Drive
Henrico, Virginia 23233

Orders/Consent Orders referred to in these minutes are available upon request

CALL TO ORDER: A meeting of a panel of the Board of Pharmacy ("Board") was called to order at 1:39 p.m.

PRESIDING: Ryan Logan, Chair

MEMBERS PRESENT: Melvin Boone
Freeda Cathcart
Michael Elliott
Rafael Saenz
Rebecca Thornbury

STAFF PRESENT: Caroline D. Juran, Executive Director
Ellen Shinaberry, Deputy Executive Director
James Rutkowski, Assistant Attorney General
Mykl Egan, DHP Adjudication Specialist

QUORUM: With six (6) members of the Board present, a quorum was established.

ELIZABETH MULUGETA
Registration No. 0230-015307

A formal hearing was held in the matter of Elizabeth Mulugeta to discuss allegations that she may have violated certain laws and regulations governing the practice of pharmacy technicians in Virginia.

Mykl D. Egan, DHP Adjudication Specialist, presented the case.

Ms. Mulugeta was not present.

Rose DeMatteo, DHP Compliance Case Manager, testified in person on behalf of the Commonwealth.

CLOSED MEETING:

Upon a motion by Mr. Elliott, and duly seconded by Ms. Cathcart, the panel voted 5-0, to convene a closed meeting pursuant to § 2.2-3711(A)(27) of the Code of Virginia ("Code"), for the purpose of deliberation to reach a decision regarding the matter of Elizabeth Mulugeta. Additionally, he moved that Caroline Juran, Ellen Shinaberry and Jim Rutkowski attend the closed meeting.

RECONVENE:

Having certified that the matters discussed in the preceding closed meeting met the requirements of § 2.2-3712 of the Code, the quorum re-convened an open meeting and announced the decision.

DECISION:

Upon a motion by Ms. Cathcart, and duly seconded by Mr. Boone, the panel voted 6-0 to accept the Findings and Fact and Conclusions of Law proposed by Mr. Egan and amended by the board.


Upon a motion by Mr. Elliott, and duly seconded by Ms. Thornbury, the panel voted 6-0 to issue an Order to reprimand Ms. Mulugeta and that states she must complete 15 hours of continuing education not obtained prior to the year 2015 within 60 days of the Order being entered.

ADJOURNED:

With all business concluded, the meeting adjourned at 2:25 p.m.



Ryan Logan, Chair



Caroline D. Juran
Executive Director

6/21/18
Date

(FINAL/APPROVED)

**VIRGINIA BOARD OF PHARMACY
PUBLIC HEARING FOR SCHEDULING CERTAIN CHEMICALS**

March 29, 2018
Second Floor
Board Room 4

Perimeter Center
9960 Mayland Drive
Henrico, Virginia 23233-1463

CALL TO ORDER: The public hearing was called to order at 9:13 a.m.

PRESIDING: Ryan K. Logan, Chairman

MEMBERS PRESENT: Jody Allen
Melvin L. Boone, Sr.
Freeda Cathcart
Sheila K. W. Elliott
Rafael Saenz
Rebecca Thornbury

MEMBERS ABSENT: Michael I. Elliott
Cynthia Warriner

STAFF PRESENT: Caroline D. Juran, Executive Director
J. Samuel Johnson, Jr. Deputy Executive Director
Beth O'Halloran, Deputy Executive Director
Ellen B. Shinaberry, Deputy Executive Director
Barbara Allison-Bryan, Chief Deputy Director, DHP
James Rutkowski, Assistant Attorney General
Elaine J. Yeatts, Senior Policy Analyst, DHP
Sylvia Tamayo-Suijk, Executive Assistant

QUORUM: With seven members present, a quorum was established.

**PUBLIC HEARING FOR
SCHEDULING CERTAIN
CHEMICALS:**

Pursuant to subsection D of §54.1-3443 of the Code, a public hearing to consider placement of chemical substances in Schedule I of the Drug Control Act was held. If approved by the Board of Pharmacy, the placement of these substances in Schedule I in the Virginia Drug Control Act shall go into effect 30 days following publication of the proposed regulation and remain in effect for a period of 18 months. The chemicals will then be de-scheduled unless a general law is passed by the General Assembly placing the chemicals into Schedule I.

CALL FOR COMMENT: Mr. Logan called for comment to consider placement of the following chemical substances into Schedule I:

Classified as research chemicals:

- 2-(ethylamino)-2-phenyl-cyclohexanone (other name: deschloro-N-ethyl-ketamine)
- 3,4-methylenedioxy-N-tert-butylcathinone
- 4-fluoro-N-ethylamphetamine
- beta-keto-4-bromo-2,5-dimethoxyphenethylamine (other name: bk-2C-B)

Classified as powerful synthetic opioids:


- N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-butenamide (other name: Crotonyl fentanyl)
- 2-(3,4-dichlorophenyl)-N-[2-(dimethylamino)cyclohexyl]-N-methylacetamide (other name: U-51754)
- N-phenyl-N-[4-phenyl-1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name: 4-phenylfentanyl)

PUBLIC COMMENT:

Public comment was provided by Scott Maye, Director of Chemistry Department, Virginia Department of Forensic Science. Mr. May requested that the Board schedule the four chemicals classified as research chemicals and the three chemicals classified as powerful synthetic opioids.

ADJOURN:

The public hearing adjourned at 9:17 am.



Ryan K. Logan, Chairman

Caroline D. Juran, Executive Director

6/21/18

Date

Date